- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Lilly Launches Online Training for Patient Advocates
An interactive training program designed “to help patient advocates better influence decisions related to access to new medicines” was launched today by Eli Lilly.
An interactive training program designed “to help patient advocates better influence decisions related to access to new medicines” was launched today by Eli Lilly.
eMEET (Medicine Evaluation Educational Training) is designed to help patient advocates “navigate the complex world of medicines development, evaluation and assessment.”
It uses video presentations, animations and exercises to show how patients’ experiences are integrated into scientifically based HTA decisions, with training program modules focused on ‘the journey of a medicine’, ‘an introduction to HTA’, ‘HTA in practice’ and ‘patient advocacy group participation in HTA’.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
